<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9286">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05701280</url>
  </required_header>
  <id_info>
    <org_study_id>REDD 0084</org_study_id>
    <nct_id>NCT05701280</nct_id>
  </id_info>
  <brief_title>Pilot/Pivotal Study of DBS+Rehab After Stroke</brief_title>
  <acronym>RESTORE</acronym>
  <official_title>Rehab With Electrical Stimulation Therapy to Optimize Rehabilitation Effect (RESTORE): A Pivotal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enspire DBS Therapy, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enspire DBS Therapy, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RESTORE Stroke Study will evaluate the safety and effectiveness of DBS+Rehab for treating&#xD;
      arm weakness and reduced function after a stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RESTORE Stroke Study combines two phases of study under one protocol (pilot/pivotal). The&#xD;
      first phase has a sample size of 40 subjects. The second phase has an estimated sample size&#xD;
      of 162 subjects which may be adjusted based on analysis of the first phase.&#xD;
&#xD;
      Each subject will be implanted with the DBS system, undergo DBS program optimization, and be&#xD;
      randomized to test treatment (Tt) or active-control treatment (Ct). After randomization, all&#xD;
      subjects will participate in a five-month outpatient rehabilitation therapy program. After&#xD;
      five months of blinded randomized testing, subjects assigned to active-control treatment (Ct)&#xD;
      will cross over to receive test treatment (Tt) and participate in a second five-month therapy&#xD;
      program.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2023</start_date>
  <completion_date type="Anticipated">June 2030</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blinded, randomized, parallel study with partial crossover.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants, Care Providers (Therapists), Investigators, and Outcome Assessors do not know to which group the participants are randomized.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fugl-Meyer Assessment, Upper Extremity sub-scale (FMA-UE)</measure>
    <time_frame>Week-12 to Week-32</time_frame>
    <description>The change in FMA-UE is significantly greater for subjects who receive Test treatment (Tt) than Control treatment (Ct).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fugl-Meyer Assessment, Upper Extremity sub-scale (FMA-UE)</measure>
    <time_frame>Week-12 to Week-32</time_frame>
    <description>The change in FMA-UE for subjects who receive Test treatment (Tt) is significantly above a clinically important difference (CID)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fugl-Meyer Assessment, Upper Extremity sub-scale (FMA-UE)</measure>
    <time_frame>Week-32, Week-40 and Week 52</time_frame>
    <description>Exploratory endpoints will be examined for the group originally assigned to Control treatment after crossover.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Stroke</condition>
  <condition>Upper Extremity Paresis</condition>
  <arm_group>
    <arm_group_label>DBS+Rehab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active-DBS combined with motor rehabilitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rehab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control-DBS combined with motor rehabilitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Deep Brain Stimulation</intervention_name>
    <description>Deep Brain Stimulation (DBS) of the dentate nucleus area of the cerebellum plus motor rehabilitation to improve upper-extremity function.</description>
    <arm_group_label>DBS+Rehab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rehabilitation</intervention_name>
    <description>Motor rehabilitation to improve upper-extremity function.</description>
    <arm_group_label>Rehab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Ischemic stroke, with an initial incident occurring between 12 months to 6 years&#xD;
             before implant, resulting in residual upper extremity hemiparesis.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Previous or subsequent cerebrovascular events resulting in residual upper extremity&#xD;
             impairment&#xD;
&#xD;
          -  Brain lesions with significant involvement of the brainstem, cerebellum, or thalamus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Stevenson</last_name>
      <phone>216-445-0926</phone>
      <email>STEVENK12@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Andre Machado, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 9, 2023</study_first_submitted>
  <study_first_submitted_qc>January 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2023</study_first_posted>
  <last_update_submitted>March 17, 2023</last_update_submitted>
  <last_update_submitted_qc>March 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Deep Brain Stimulation</keyword>
  <keyword>DBS</keyword>
  <keyword>Physical Therapy</keyword>
  <keyword>Rehabilitation</keyword>
  <keyword>Brain Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Paresis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

